Skip to main content
SpringerLink
Log in

Immune-Inflammatory Disorders in the ICU

  • Chapter
  • First Online:
Best 2022 Clinical Cases in Intensive Care Medicine

Part of the book series: Lessons from the ICU ((LEICU))

  • 477 Accesses

Abstract

Critical illnesses are frequently associated with and complicated by immune-inflammatory disorders, either as preexisting comorbidities or new diseases exacerbated by critical care status. Systemic manifestations of preexisting immune-inflammatory disorders can become serious life-threatening conditions, thus requiring ICU support. Apart from these systemic immune-inflammatory disorders, hyperinflammatory response to a trigger such as sepsis, infection, or malignancy may occur and result in widespread clinical consequences. Treatment strategies of systemic immune-inflammatory disorders are based on the type of diseases and aim to downregulate an overreactive immune system and to control the clinical manifestations of these disorders. Steroids, disease-modifying antirheumatic drugs, nonsteroidal anti-inflammatory drugs, and the new biologic disease-modifying agents are usually used for treatment. The aim of this chapter is to briefly characterize and discuss the intensive care management of immune-inflammatory diseases that can affect critically ill patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Duggal NA, Snelson C, Shaheen U, Pearce V, Lord JM. Innate and adaptive immune dysregulation in critically ill ICU patients. Sci Rep. 2018;8:10186.

    PubMed  PubMed Central  Google Scholar 

  2. Quintero OL, Rojas-Villarraga A, Mantilla RD, Anaya J-M. Autoimmune diseases in the intensive care unit. An update. Autoimmun Rev. 2013;12:380–95.

    PubMed  Google Scholar 

  3. Janssen NM, Karnad DR, Guntupalli KK. Rheumatologic diseases in the intensive care unit: epidemiology, clinical approach, management, and outcome. Crit Care Clin. 2002;18:729–48.

    PubMed  Google Scholar 

  4. Bernal-Macías S, Reyes-Beltrán B, Molano-González N, Augusto Vega D, Bichernall C, Díaz LA, et al. Outcome of patients with autoimmune diseases in the intensive care unit: a mixed cluster analysis. Lupus Sci Med. 2015;2:e000122.

    PubMed  PubMed Central  Google Scholar 

  5. Bell A, Tattersall R, Wenham T. Rheumatological conditions in critical care. BJA Educ. 2016;16:427–33.

    Google Scholar 

  6. Skinner J, Yankey B, Shelton BK. Hemophagocytic Lymphohistiocytosis. AACN Adv Crit Care. 2019;30:151–64.

    PubMed  Google Scholar 

  7. Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA. Cytokine release syndrome: current perspectives. ImmunoTargets Ther. 2019;8:43–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–38.

    CAS  PubMed  Google Scholar 

  9. Fajgenbaum DC, June CH. Cytokine storm. Longo DL, editor. N Engl J Med. 2020;383:2255–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Nagao Y, Harada H, Yamanaka H, Fukuda K. Possible mediators for systemic capillary leak syndrome. Am J Med. 2011;124:e7–9.

    PubMed  Google Scholar 

  11. Cornell RF, Hari P, Drobyski WR. Engraftment syndrome after autologous stem cell transplantation: an update unifying the definition and management approach. Biol Blood Marrow Transplant. 2015;21:2061–8.

    PubMed  PubMed Central  Google Scholar 

  12. Lambert M, Launay D, Hachulla E, Morell-Dubois S, Soland V, Queyrel V, et al. High-dose intravenous immunoglobulins dramatically reverse systemic capillary leak syndrome. Crit Care Med. 2008;36:2184–7.

    CAS  PubMed  Google Scholar 

  13. Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell. 2009;16:209–21.

    CAS  PubMed  Google Scholar 

  14. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci. 2008;121:2115–22.

    CAS  PubMed  Google Scholar 

  15. Tahirkheli NK. Treatment of the systemic capillary leak syndrome with terbutaline and theophylline: a case series. Ann Intern Med. 1999;130:905–9.

    CAS  PubMed  Google Scholar 

  16. Clarkson B, Thompson D, Horwith M, Luckey EH. Cyclical edema and shock due to increased capillary permeability. Am J Med. 1960;29:193–216.

    CAS  PubMed  Google Scholar 

  17. Lee YS, Kim SY, Kwon CW, Song HG, Lee YK, Kim HJ, et al. Two cases of systemic capillary leak syndrome that were treated with pentastarch. Korean J Intern Med. 2007;22:130.

    PubMed  PubMed Central  Google Scholar 

  18. Bouhaja B. Adult respiratory distress syndrome complicating a systemic capillary leak syndrome. Intensive Care Med. 1994;20:307–8.

    CAS  PubMed  Google Scholar 

  19. Casadei Gardini A, Aquilina M, Oboldi D, Lucchesi A, Carloni S, Tenti E, et al. Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease. BMC Cancer. 2013;13:542.

    PubMed  PubMed Central  Google Scholar 

  20. Fábregues F, Balasch J, Ginès P, Manau D, Jiménez W, Arroyo V, et al. Ascites and liver test abnormalities during severe ovarian hyperstimulation syndrome. Am J Gastroenterol. 1999;94:994–9.

    PubMed  Google Scholar 

  21. Almawi WY, Beyhum HN, Rahme AA, Rieder MJ. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol. 1996;60:563–72.

    CAS  PubMed  Google Scholar 

  22. Xie Z, Chan EC, Long LM, Nelson C, Druey KM. High-dose intravenous immunoglobulin therapy for systemic capillary leak syndrome (Clarkson disease). Am J Med. 2015;128:91–5.

    CAS  PubMed  Google Scholar 

  23. Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome in children: an important diagnostic consideration in fever of unknown origin. Clin Infect Dis. 2003;36:306–12.

    PubMed  Google Scholar 

  24. Chen X, Wang F, Zhang Y, Teng W, Wang M, Nie D, et al. Genetic variant spectrum in 265 Chinese patients with hemophagocytic lymphohistiocytosis: molecular analyses of PRF1, UNC13D, STX11, STXBP2, SH2D1A, and XIAP. Clin Genet. 2018;94:200–12.

    CAS  PubMed  Google Scholar 

  25. Créput C, Galicier L, Buyse S, Azoulay E. Understanding organ dysfunction in hemophagocytic lymphohistiocytosis. Intensive Care Med. 2008;34:1177–87.

    PubMed  Google Scholar 

  26. Halacli B, Unver N, Halacli SO, Canpinar H, Ersoy EO, Ocal S, et al. Investigation of hemophagocytic lymphohistiocytosis in severe sepsis patients. J Crit Care. 2016;35:185–90.

    PubMed  Google Scholar 

  27. Rivière S, Galicier L, Coppo P, Marzac C, Aumont C, Lambotte O, et al. Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med. 2014;127:1118–25.

    PubMed  Google Scholar 

  28. Daver N, McClain K, Allen CE, Parikh SA, Otrock Z, Rojas-Hernandez C, et al. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017;123:3229–40.

    PubMed  Google Scholar 

  29. Lin M, Park S, Hayden A, Giustini D, Trinkaus M, Pudek M, et al. Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. Ann Hematol. 2017;96:1241–51.

    CAS  PubMed  Google Scholar 

  30. Valade S, Azoulay E, Galicier L, Boutboul D, Zafrani L, Stepanian A, et al. Coagulation disorders and bleedings in critically ill patients with hemophagocytic lymphohistiocytosis. Medicine (Baltimore). 2015;94:e1692.

    PubMed  Google Scholar 

  31. Allen CE, McClain KL. Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematology. 2015;2015:177–82.

    PubMed  Google Scholar 

  32. Heidenreich F, Vincent A, Roberts A, Newsom-Davis J. Epitopes on human acetylcholine receptor defined by monoclonal antibodies and myasthenia gravis sera. Autoimmunity. 1988;1:285–97.

    CAS  PubMed  Google Scholar 

  33. Luchanok V, Kaminski HJ. Natural history of myasthenia gravis. Neurol Fac Publ. 2012:90–107.

    Google Scholar 

  34. Evoli A. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126:2304–11.

    PubMed  Google Scholar 

  35. Robert P. Lisak. Handbook of myasthenia gravis and myasthenic syndromes. Dekker M. 1994.

    Google Scholar 

  36. Engel H. Natural history of myasthenia gravis. Myasthenia Gravis Myasthenic Disord. 2012:90–107.

    Google Scholar 

  37. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis. Neurology. 1996;46:1607–12.

    CAS  PubMed  Google Scholar 

  38. Spillane J, Taylor C, Hirsch NP, Kullmann DM, Howard RS. 171 Myasthenic crisis in the intensive care unit: a 10-year review. J Neurol Neurosurg Psychiatry. 2012;83:e1.128.

    Google Scholar 

  39. Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology. 2009;72:1548–54.

    CAS  PubMed  Google Scholar 

  40. Lal V, Prabhakar S, Agarwal R, Sharma S. Clinical profile and outcome of myasthenic crisis in a tertiary care hospital: a prospective study. Ann Indian Acad Neurol. 2013;16:203–7.

    PubMed  PubMed Central  Google Scholar 

  41. DeBaets M, Oosterhuis H. Immunopathology of myasthenia gravis. 1993.

    Google Scholar 

  42. Gilhus NE, Aarli JA, Christensson B, Matre R. Rabbit antiserum to a citric acid extract of human skeletal muscle staining thymomas from myasthenia gravis patients. J Neuroimmunol. 1984;7:55–64.

    CAS  PubMed  Google Scholar 

  43. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology. 1998;50:1778–83.

    CAS  PubMed  Google Scholar 

  44. Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: Association of British Neurologists’ management guidelines. Pract Neurol. 2015;15:199–206.

    PubMed  Google Scholar 

  45. Farrugia ME, Goodfellow JA. A practical approach to managing patients with myasthenia gravis—opinions and a review of the literature. Front Neurol. 2020;11:11.

    Google Scholar 

  46. Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76:2017–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Benditt JO. Respiratory care of patients with neuromuscular disease. Respir Care. 2019;64:679–88.

    PubMed  Google Scholar 

  48. Chang C-C, Yeh J-H, Chiu H-C, Chen Y-M, Jhou M-J, Liu T-C, et al. Utilization of decision tree algorithms for supporting the prediction of intensive care unit admission of myasthenia gravis: a machine learning-based approach. J Pers Med. 2022;12:12.

    Google Scholar 

  49. Damian MS, Wijdicks EFM. The clinical management of neuromuscular disorders in intensive care. Neuromuscul Disord. 2019;29:85–96.

    PubMed  Google Scholar 

  50. Still GF. On a form of chronic joint disease in children. Med Chir Trans. 1897;80:47–59.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Mavragani CP, Spyridakis EG, Koutsilieris M. Adult-onset Still’s disease: from pathophysiology to targeted therapies. Int J Inflam. 2012;2012:1–10.

    Google Scholar 

  52. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun. 2018;93:24–36.

    PubMed  Google Scholar 

  53. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still’s disease. Autoimmun Rev. 2014;13:708–22.

    CAS  PubMed  Google Scholar 

  54. Néel A, Wahbi A, Tessoulin B, Boileau J, Carpentier D, Decaux O, et al. Diagnostic and management of life-threatening adult-onset Still disease: a French nationwide multicenter study and systematic literature review. Crit Care. 2018;22:88.

    PubMed  PubMed Central  Google Scholar 

  55. Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70:118–36.

    CAS  PubMed  Google Scholar 

  56. Wang M-Y, Jia J-C, Yang C-D, Hu Q-Y. Pathogenesis, disease course, and prognosis of adult-onset Still’s disease: an update and review. Chin Med J. 2019;132:2856–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Ruscitti P, Cipriani P, Ciccia F, Masedu F, Liakouli V, Carubbi F, et al. Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers. Autoimmun Rev. 2017;16:16–21.

    CAS  PubMed  Google Scholar 

  58. Batu E, Erden A, Seyhoğlu E, Kilic L, Büyükasık Y, Karadag O, et al. Assessment of the HScore for reactive haemophagocytic syndrome in patients with rheumatic diseases. Scand J Rheumatol. 2017;46:44–8.

    CAS  PubMed  Google Scholar 

  59. Mitrovic S, Fautrel B. Complications of adult-onset Still’s disease and their management. Expert Rev Clin Immunol. 2018;14:351–65.

    CAS  PubMed  Google Scholar 

  60. Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of adult-onset Still’s disease. Clin Rheumatol. 2014;33:305–14.

    PubMed  PubMed Central  Google Scholar 

  61. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–30.

    CAS  PubMed  Google Scholar 

  62. Dua A, Siddiqui M, Putman M. Adult-onset Still’s disease: current challenges and future prospects. Open Access Rheumatol Res Rev. 2016:17.

    Google Scholar 

  63. Fautrel B, Borget C, Rozenberg S, Meyer O, Le Loët X, Masson C, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still’s disease. J Rheumatol. 1999;26:373–8.

    CAS  PubMed  Google Scholar 

  64. Ruscitti P, Ursini F, Cipriani P, De Sarro G, Giacomelli R. Biologic drugs in adult onset Still’s disease: a systematic review and meta-analysis of observational studies. Expert Rev Clin Immunol. 2017;13:1089–97.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Intensive Care Unit, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey

    Mehmet Yildirim

  2. Adult Intensive Care Unit, Oxford University Hospitals NHS foundation trust, Level 1, John Radcliffe Hospital, Headley Way, Oxford, UK

    Ahmed Zaher

  3. Anesthesia and Intensive Care, IRRCS San Martino Policlinico Hospital, Genoa, Italy

    Denise Battaglini

Authors
  1. Mehmet Yildirim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmed Zaher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Denise Battaglini
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Intensive Care Medicine, Hospital Universitario Río Hortega, Valladolid, Spain

    David Pérez-Torres

  2. Hospital Universitari Vall d'Hebron, Intensive Care Medicine Department, Barcelona, Spain

    María Martínez-Martínez

  3. Department of Anesthesiology and Intensive Care Medicine (CCM/CVK), Charité — Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

    Stefan J. Schaller

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yildirim, M., Zaher, A., Battaglini, D. (2023). Immune-Inflammatory Disorders in the ICU. In: Pérez-Torres, D., Martínez-Martínez, M., Schaller, S.J. (eds) Best 2022 Clinical Cases in Intensive Care Medicine. Lessons from the ICU. Springer, Cham. https://doi.org/10.1007/978-3-031-36398-6_57

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-36398-6_57

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-36397-9

  • Online ISBN: 978-3-031-36398-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation